Update on Endogenous Inhibitors of Angiogenesis

REFERENCES

• Abe M., Sato Y. cDNA microarray analysis of the gene expression profile of VEGF-activated human umbilical vein endothelial cells. Angiogenesis 2001; 4: 289–298, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Bein K., Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. Journal of Biological Chemistry 2000; 275: 32167–32173, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bergers G., Brekken R., McMahon G., Vu T. H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology 2000; 2: 737–744, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Biliran H., Jr., Sheng S. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Research 2001; 61: 8676–8682, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Brew K., Dinakarpandian D., Nagase H. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochimica et Biophysica Acta 2000; 1477: 267–283, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Chadderton N. S., Stringer S. E. Interaction of platelet factor 4 with fibroblast growth factor 2 is stabilised by heparan sulphate. International Journal of Biochemistry and Cell Biology 2003; 35: 1052–1055, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chen H., Herndon M. E., Lawler J. The cell biology of thrombospondin-1. Matrix Biology 2000; 19: 597–614, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Clark D. E., Smith S. K., He Y., Day K. A., Licence D. R., Corps A N., Lammoglia R., Charnock-Jones D. S. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biology of Reproduction 1998; 59: 1540–1548, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Coljee V. W., Rotenberg M. O., Tresini M., Francis M. K., Cristofalo V. J., Sell C. Regulation of EPC-1/PEDF in normal human fibroblasts is posttranscriptional. Journal of Cellular Biochemistry 2000; 79: 442–452, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Colorado P. C., Torre A., Kamphaus G., Maeshima Y., Hopfer H., Takahashi K., Volk R., Zamborsky E. D., Herman S., Sarkar P. K., Ericksen M. B., Dhanabal M., Simons M., Post M., Kufe D. W., Weichselbaum R. R., Sukhatme V. P., Kalluri R. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Research 2000; 60: 2520–2526, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cornelius L. A., Nehring L. C., Harding E., Bolanowski M., Welgus H. G., Kobayashi D. K., Pierce R. A., Shapiro S. D. Matrix metalloproteinases generate angiostatin: Effects on neovascularization. Journal of Immunology 1998; 161: 6845–6852, [CSA]
   PubMed Web of Science ®Google Scholar
• D'Amato R. J., Lin C. M., Flynn E., Folkman J., Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proceedings of the National Academy of Sciences of the United States of America 1994; 91: 3964–3968, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• D'Angelo G., Martini J. F., Iiri T., Fantl W. J., Martial J., Weiner R. I. 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Molecular Endocrinology 1999; 13: 692–704, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D'Angelo G., Struman I., Martial J., Weiner R. I. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proceedings of the National Academy of Sciences of the United States of America 1995; 92: 6374–6378, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dawson D. W., Pearce S. F., Zhong R., Silverstein R. L., Frazier W. A., Bouck N. P. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. Journal of Cell Biology 1997; 138: 707–717, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dawson D. W., Volpert O. V., Gillis P., Crawford S. E., Xu H., Benedict W., Bouck N. P. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 1999; 285: 245–248, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Doll J. A., Stellmach V. M., Bouck N. P., Bergh A. R., Lee C., Abramson L. P., Cornwell M. L., Pins M. R., Borensztajn J., Crawford S. E. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nature Medicine 2003; 9: 774–780, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dong Z., Kumar R., Yang X., Fidler I. J. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997; 88: 801–810, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Eming S. A., Lauer G., Cole M., Jurk S., Christ H., Hornig C., Krieg T., Weich H. A. Increased levels of the soluble variant of the vascular endothelial growth factor receptor VEGFR-1 are associated with a poor prognosis in wound healing. Journal of Investigative Dermatology 2004; 123: 799–802, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Eubank T. D., Roberts R., Galloway M., Wang Y., Cohn D E., Marsh C. B. GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice. Immunity 2004; 1: 831–842, [CSA], [CROSSREF]
   Google Scholar
• Ferrara N., Clapp C., Weiner R. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 1991; 129: 896–900, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Floquet N., Pasco S., Ramont L., Derreumaux P., Laronze J. Y., Nuzillard J. M., Maquart F. X., Alix A. J., Monboisse J. C. The antitumor properties of the α3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent. Journal of Biological Chemistry 2004; 279: 2091–2100, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fotsis T., Zhang Y., Pepper M. S., Adlercreutz H., Montesano R., Nawroth P. P., Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994; 368: 237–239, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Geiger J. H., Cnudde S. E. What the structure of angiostatin may tell us about its mechanism of action. Journal of Thrombosis and Haemostasis 2004; 2: 23–34, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gettins P. G., Simonovic M., Volz K. Pigment epithelium-derived factor (PEDF), a serpin with potent anti-angiogenic and neurite outgrowth-promoting properties. Biological Chemistry 2002; 383: 1677–1682, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Goldhar A. S., Vonderhaar B. K., Trott J. F., Hovey R. C. Prolactin-induced expression of vascular endothelial growth factor via Egr-1. Molecular and Cellular Endocrinology 2005; 232: 9–19, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hamano Y., Kalluri R. Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochemical and Biophysical Research Communications 2005; 333: 292–298, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Harrington E. O., Loffler J., Nelson P. R., Kent K. C., Simons M., Ware J. A. Enhancement of migration by protein kinase Calpha and inhibition of proliferation and cell cycle progression by protein kinase Cdelta in capillary endothelial cells. Journal of Biological Chemistry 1997; 272: 7390–7397, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Heljasvaara R., Nyberg P., Luostarinen J., Parikka M., Heikkila P., Rehn M., Sorsa T., Salo T., Pihlajaniemi T. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Experimental Cell Research 2005; 307: 292–304, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hendrix M. J. De-mystifying the mechanism(s) of maspin. Nature Medicine 2000; 6: 374–376, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hiraki Y., Kono T., Sato M., Shukunami C., Kondo J. Inhibition of DNA synthesis and tube morphogenesis of cultured vascular endothelial cells by chondromodulin-I. FEBS Letters 1997; 415: 321–324, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hiraki Y., Shukunami C. Chondromodulin-I as a novel cartilage-specific growth-modulating factor. Pediatric Nephrology 2000; 14: 602–605, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hiraki Y., Tanaka H., Inoue H., Kondo J., Kamizono A., Suzuki F. Molecular cloning of a new class of cartilage-specific matrix, chondromodulin-I, which stimulates growth of cultured chondrocytes. Biochemical and Biophysical Research Communications 1991; 175: 971–977, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hirashima M., Lu Y., Byers L., Rossant J. Trophoblast expression of fms-like tyrosine kinase 1 is not required for the establishment of the maternal-fetal interface in the mouse placenta. Proceedings of the National Academy Sciences of the United States of America 2003; 100: 15637–15642, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hosomichi J., Yasui N., Koide T., Soma K., Morita I. Involvement of the collagen I-binding motif in the anti-angiogenic activity of pigment epithelium-derived factor. Biochemical and Biophysical Research Communications 2005; 335: 756–761, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Iruela-Arispe M. L., Luque A., Lee N. Thrombospondin modules and angiogenesis. International Journal of Biochemistry and Cell Biology 2004; 36: 1070–1078, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kamphaus G. D., Colorado P. C., Panka D. J., Hopfer H., Ramchandran R., Torre A., Maeshima Y., Mier J. W., Sukhatme V. P., Kalluri R. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. Journal of Biological Chemistry 2000; 275: 1209–1215, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Karumanchi S. A., Jha V., Ramchandran R., Karihaloo A., Tsiokas L., Chan B., Dhanabal M., Hanai J. I., Venkataraman G., Shriver Z., Keiser N., Kalluri R., Zeng H., Mukhopadhyay D., Chen R. L., Lander A. D., Hagihara K., Yamaguchi Y., Sasisekharan R., Cantley L., Sukhatme V. P. Cell surface glypicans are low-affinity endostatin receptors. Molecular Cell 2001; 7: 811–822, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kirsch M., Schackert G., Black P. M. Metastasis and angiogenesis. Cancer Treatment Research 2004; 117: 285–304, [CSA]
   PubMedGoogle Scholar
• Kreuger J., Matsumoto T., Vanwildemeersch M., Sasaki T., Timpl R., Claesson-Welsh L., Spillmann D., Lindahl U. Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function. EMBO Journal 2002; 21: 6303–6311, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Larsson H., Akerud P., Nordling K., Raub-Segall E., Claesson-Welsh L., Bjork I. A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity. Journal of Biological Chemistry 2001; 276: 11996–12002, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Larsson H., Sjoblom T., Dixelius J., Ostman A., Ylinenjarvi K., Bjork I., Claesson-Welsh L. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Research 2000; 60: 6723–6729, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lijnen H. R., Ugwu F., Bini A., Collen D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 1998; 37: 4699–4702, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Luster A. D., Unkeless J. C., Ravetch J. V. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 1985; 315: 672–676, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mabjeesh N. J., Escuin D., LaVallee T. M., Pribluda V. S., Swartz G. M., Johnson M. S., Willard M. T., Zhong H., Simons J. W., Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003; 3: 363–375, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Maeshima Y., Colorado P. C., Kalluri R. Two RGD-independent α vβ3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. Journal of Biological Chemistry 2000a; 275: 23745–23750, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Maeshima Y., Colorado P. C., Torre A., Holthaus K. A., Grunkemeyer J. A., Ericksen M. B., Hopfer H., Xiao Y., Stillman I. E., Kalluri R. Distinct anti-tumor properties of a type IV collagen domain derived from basement membrane. Journal of Biological Chemistry 2000a; 275: 21340–21348, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Maione T. E., Gray G. S., Petro J., Hunt A. J., Donner A. L., Bauer S. I., Carson H. F., Sharpe R. J. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990; 247: 77–79, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Maynard S. E., Min J. Y., Merchan J., Lim K. H., Li J., Mondal S., Libermann T. A., Morgan J. P., Sellke F. W., Stillman I. E., Epstein F. H., Sukhatme V. P., Karumanchi S. A. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. Journal of Clinical Investigation 2003; 111: 649–658, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• McGowen R., Biliran H., Jr., Sager R., Sheng S. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. Cancer Research 2000; 60: 4771–4778, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Michalak M., Milner R. E., Burns K., Opas M. Calreticulin. Biochemical Journal 1992; 285: 681–692, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mori Y., Hiraki Y., Shukunami C., Kakudo S., Shiokawa M., Kagoshima M., Mano H., Hakeda Y., Kurokawa T., Suzuki F., Kumegawa M. Stimulation of osteoblast proliferation by the cartilage-derived growth promoting factors chondromodulin-I and -II. FEBS Letters 1997; 406: 310–314, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Moser T. L., Stack M. S., Asplin I., Enghild J. J., Hojrup P., Everitt L., Hubchak S., Schnaper H. W., Pizzo S. V. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 1999; 96: 2811–2816, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Moses M. A. A cartilage-derived inhibitor of neovascularization and metalloproteinases. Clinical and Experimental Rheumatology 1993; 11(Suppl 8)S67–S69, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Nakamichi Y., Shukunami C., Yamada T., Aihara K., Kawano H., Sato T., Nishizaki Y., Yamamoto Y., Shindo M., Yoshimura K., Nakamura T., Takahashi N., Kawaguchi H., Hiraki Y., Kato S. Chondromodulin I is a bone remodeling factor. Molecular and Cellular Biology 2003; 23: 636–644, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Neville L. F., Mathiak G., Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): A novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine and Growth Factor Reviews 1997; 8: 207–219, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Noh Y. H., Matsuda K., Hong Y. K., Kunstfeld R., Riccardi L., Koch M., Oura H., Dadras S. S., Streit M., Detmar M. An N-terminal 80 kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo. Journal of Investigative Dermatology 2003; 121: 1536–1543, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• O'Reilly M. S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W. S., Flynn E., Birkhead J. R., Olsen B. R., Folkman J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–285, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• O'Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R. A., Moses M., Lane W. S., Cao Y., Sage E. H., Folkman J. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315–328, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• O'Reilly M S., Pirie-Shepherd S., Lane W. S., Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999a; 285: 1926–1928, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• O'Reilly M. S., Wiederschain D., Stetler-Stevenson W. G., Folkman J., Moses M. A. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. Journal of Biological Chemistry 1999b; 274: 29568–29571, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Panka D. J., Mier J. W. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. Journal of Biologial Chemistry 2003; 278: 37632–37636, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Patterson B. C., Sang Q. A. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). Journal of Biological Chemistry 1997; 272: 28823–28825, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pike S. E., Yao L., Setsuda J., Jones K. D., Cherney B., Appella E., Sakaguchi K., Nakhasi H., Atreya C. D., Teruya-Feldstein J., Wirth P., Gupta G., Tosato G. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 1999; 94: 2461–2468, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pozzi A., Wary K. K., Giancotti F. G., Gardner H. A. Integrin α 1β 1 mediates a unique collagen-dependent proliferation pathway in vivo. Journal of Cell Biology 1998; 142: 587–594, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rodriguez-Manzaneque J. C., Lane T. F., Ortega M. A., Hynes R. O., Lawler J., Iruela-Arispe M. L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proceedings of the National Acadeamy Science of United States of America 2001; 98: 12485–12490, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Roemisch J., Gray E., Hoffmann J. N., Wiedermann C. J. Antithrombin: A new look at the actions of a serine protease inhibitor. Blood Coagulation and Fibrinolysis 2002; 13: 657–670, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sasaki T., Larsson H., Kreuger J., Salmivirta M., Claesson-Welsh L., Lindahl U., Hohenester E., Timpl R. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO Journal 1999; 18: 6240–6248, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Shen J. K., Yang X. R., Sato Y., Campochiaro P. A. Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. FASEB Journal 2006; 20: 723–725, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Shibuya T., Watanabe K., Yamashita H., Shimizu K., Miyashita H., Abe M., Moriya T., Ohta H., Sonoda H., Shimosegawa T., Tabayashi K., Sato Y. Isolation of vasohibin-2 as a sole homologue of VEGF-inducible endothelium-derived angiogenesis inhibitor vasohibin: A comparative study on their expressions. Arteriosclerosis, Thrombosis, and Vascular Biology 2006; 26: 1051–1057, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Shimizu K., Watanabe K., Yamashita H., Abe M., Yoshimatsu H., Ohta H., Sonoda H., Sato Y. Gene regulation of a novel angiogenesis inhibitor, vasohibin, in endothelial cells. Biochemical and Biophysical Research Communications 2005; 327: 700–706, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sidky Y. A., Borden E. C. Inhibition of angiogenesis by interferons: Effects on tumor- and lymphocyte-induced vascular responses. Cancer Research 1987; 47: 5155–5161, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sim B. K., MacDonald N. J., Gubish E. R. Angiostatin and endostatin: Endogenous inhibitors of tumor growth. Cancer and Metastasis Reviews 2000; 19: 181–190, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Slaton J. W., Karashima T., Perrotte P., Inoue K., Kim S J., Izawa J., Kedar D., McConkey D. J., Millikan R., Sweeney P., Yoshikawa C., Shuin T., Dinney C. P. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clinical Cancer Research 2001; 7: 2840–2853, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Slaton J. W., Perrotte P., Inoue K., Dinney C. P., Fidler I. J. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clinical Cancer Research 1999; 5: 2726–2734, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Stathakis P., Fitzgerald M., Matthias L. J., Chesterman C. N., Hogg P. J. Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells. Journal of Biological Chemistry 1997; 272: 20641–20645, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Steele F. R., Chader G. J., Johnson L. V., Tombran-Tink J. Pigment epithelium-derived factor: Neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proceedings of the National Academy of the Sciences of the United States of America 1993; 90: 1526–1530, [CSA]
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson W. G., Seo D. W. TIMP-2: An endogenous inhibitor of angiogenesis. Trends in Molecular Medicine 2005; 11: 97–103, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Streit M., Velasco P., Brown L. F., Skobe M., Richard L., Riccardi L., Lawler J., Detmar M. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. American Journal of Pathology 1999; 155: 441–452, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Struman I., Bentzien F., Lee H., Mainfroid V., D'Angelo G., Goffin V., Weiner R. I., Martial J. A. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: An efficient mechanism for the regulation of angiogenesis. Proceedings of the National Academy of the Sciences of the United States of America 1999; 96: 1246–1251, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sudhakar A., Sugimoto H., Yang C., Lively J., Zeisberg M., Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α 5β1 integrins. Proceedings of the National Academy of Sciences United States of America 2003; 100: 4766–4771, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tarui T., Majumdar M., Miles L. A., Ruf W., Takada Y. Plasmin-induced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin. Journal of Biological Chemistry 2002; 277: 33564–33570, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tarui T., Miles L. A., Takada Y. Specific interaction of angiostatin with integrin αvβ3 in endothelial cells. Journal of Biological Chemistry 2001; 276: 39562–39568, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Troyanovsky B., Levchenko T., Mansson G., Matvijenko O., Holmgren L. Angiomotin: An angiostatin binding protein that regulates endothelial cell migration and tube formation. Journal of Cell Biology 2001; 152: 1247–1254, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Vlodavsky I., Korner G., Ishai-Michaeli R., Bashkin P., Bar-Shavit R., Fuks Z. Extracellular matrix-resident growth factors and enzymes: Possible involvement in tumor metastasis and angiogenesis. Cancer and Metastasis Reviews 1990; 9: 203–226, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Volpert O. V., Zaichuk T., Zhou W., Reiher F., Ferguson T. A., Stuart P. M., Amin M., Bouck N. P. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Natural Medicine 2002; 8: 349–357, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• von Marschall Z., Scholz A., Cramer T., Schafer G., Schirner M., Oberg K., Wiedenmann B., Hocker M., Rosewicz S. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. Journal of the National Cancer Institute 2003; 95: 437–448, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Watanabe K., Hasegawa Y., Yamashita H., Shimizu K., Ding Y., Abe M., Ohta H., Imagawa K., Hojo K., Maki H., Sonoda H., Sato Y. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. Journal of Clinical Investigation 2004; 114: 898–907, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wickstrom S. A., Alitalo K., Keski-Oja J. An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. Journal of Biological Chemistry 2004; 279: 20178–20185, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Yamaguchi S., Iwata K., Shibuya M. Soluble Flt-1 (soluble VEGFR-1), a potent natural antiangiogenic molecule in mammals, is phylogenetically conserved in avians. Biochemical and Biophysical Research Communications 2002; 291: 554–559, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Yang Q., Rasmussen S. A., Friedman J. M. Mortality associated with Down's syndrome in the USA from 1983 to 1997: A population-based study. Lancet 2002; 359: 1019–1025, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Yang J., Richmond A. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Molecular Therapy 2004; 9: 846–855, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Yao L., Pike S. E., Tosato G. Laminin binding to the calreticulin fragment vasostatin regulates endothelial cell function. Journal of Leukocyte Biology 2002; 71: 47–53, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Zhang D., Kaufman P. L., Gao G., Saunders R. A., Ma J. X. Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats. Diabetologia 2001; 44: 757–765, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zhang M., Volpert O., Shi Y. H., Bouck N. Maspin is an angiogenesis inhibitor. Natural Medicine 2000; 6: 196–199, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zhang W., Chuang Y. J., Swanson R., Li J., Seo K., Leung L., Lau L. F., Olson S. T. Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells. Blood 2004; 103: 1185–1191, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zhou J., Giannakakou P. Targeting microtubules for cancer chemotherapy. Current Medicinal Chemistry and Anti-Cancer Agents 2005; 5: 65–71, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Zorick T. S., Mustacchi Z., Bando S Y., Zatz M., Moreira-Filho C. A., Olsen B., Passos-Bueno M. R. High serum endostatin levels in Down syndrome: Implications for improved treatment and prevention of solid tumours. European Journal of Human Genetics 2001; 9: 811–814, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Zou Z., Anisowicz A., Hendrix M. J., Thor A., Neveu M., Sheng S., Rafidi K., Seftor E., Sager R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994; 263: 526–529, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Zou Z., Gao C., Nagaich A. K., Connell T., Saito S., Moul J. W., Seth P., Appella E., Srivastava S. p53 regulates the expression of the tumor suppressor gene maspin. Journal of Biological Chemistry 2000; 275: 6051–6054, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar